Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism
Figure 1
Chronic treatment effects on pain behaviour. Comparison of PEA-effects in PPAR- and mice. (a) Response to a mechanical noxious stimulus on the ipsilateral paw 14 days after CCI evaluated by Randall-Selitto test. (b) Response to a mechanical nonnoxious stimulus evaluated by Von Frey test. PEA (30 mg kg−1) was daily s.c. administered for 14 days starting from the day of operation. Each value represents the mean of 2 experiments with 12 mice per group. versus vehicle-treated mice.
